Latest News

  • Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Read More
  • Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference Read More
  • Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder Read More

Investors

Learn More

Working at Alkermes

Join Our Team